N/A N=78 The Impact of Training With Whole Body-EMS
Healthy
Primary: Mean Change in Reactive Hyperemia Index (RHI) — 0.02; -0.26 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=37 A Single Arm Pilot Study to Refine a Novel Approach to Exercise Promotion Based on Affect-regulation
Breast Cancer
Primary: Acceptability of the Affect-regulated Exercise Prescription Measured Using the Treatment Acceptability and Preferences (TAP) Measure — 3.31 score on a scale
N/A N=1,073 Music & MEmory: A Pragmatic TRial for Nursing Home Residents With ALzheimer's Disease_part1
Dementia
Primary: Frequency of Agitated and Aggressive Behaviors (Staff Report) — 50.31; 48.04 score on scale — p=< 0.05
Phase 2 N=60 Resveratrol to Enhance Vitality and Vigor in Elders
Mitochondrial Function · Physical Function
Primary: Change From Baseline in Mitochondrial Respiration in Muscle — -3.05; -4.82; -4.56 nmol O2/s/mg wwt
N/A N=102 Evaluation of Rotation With a Multifocal Toric Contact Lens
Visual Acuity
Primary: Proportion of Eyes With Absolute Rotation ≤ 10 Degrees — 0.9167; 0.8873 Proportion
Phase 3 N=652 A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Overall Response Rate (ORR) Assessed by the Investigator — 83.5; 74.2 percentage of participants — p=<0.0001
Phase 4 N=867 Sculptra Aesthetic Post-Approval Study
Nasolabial Fold Contour Deficiencies · Wrinkles
Primary: Percentage of Participants With Any Injection Site Nodule and/or Papule — 30.52; 24.84 percentage of participants
Phase 3 N=4,044 ACTIV-2: A Study for Outpatients With COVID-19
Coronavirus · Covid19
Primary: COVID-19 Symptom Duration (Phase 2) — 21.0; 18.5; 24.0; 20.5 Days
Phase 2 N=20 Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut Allergy
Peanut Allergy
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 15; 5; 0; 0 Participants
Phase 1 N=32 A Study in Healthy Humans to Assess the Relative Bioavailability of One Fixed-dose Combination Tablet Empagliflozin/Metformin Versus Jardiance® Tablet and Glifage® Tablet Administered Together
Healthy
Primary: Dose-normalized Area Under the Concentration-time Curve of Empagliflozin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 117.15…
N/A N=51 Marijuana Use, Strength Training, and Alcohol Consumption (MUSTAC) Study
Chronic Pain
Primary: Alcohol Demand: Breakpoint — -6.00; -2.07; -1.81; -1.09 dollars/drink — p=.26
Phase 2 N=16 Remote Observed Dosing of Suboxone to Improve Clinical Practice
Opioid-use Disorder · Opioid Dependence · Opiate Dependence
Primary: Mean Urinary Buprenorphine Levels — 861; 287 ng/ml — p=.1
N/A N=150 A Randomized, Study to Evaluate the Iovera° Device in Treating Pain Associated With Total Knee Arthroplasty
Arthritis of the Knee
Primary: Cumulative Consumption of Opioids Total Daily Morphine Equivalent (TME) (mg/Day) — 23.9; 27.1 mg/day
Phase 2 N=89 Conversion to Envarsus Post Kidney Transplant Protects Against BK Infection
Renal Transplant Infection
Primary: Participants Will Experience Less BK Infection Episodes Based on Viruria Results.
Phase 4 N=100 Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features
Pre-Eclampsia · HELLP Syndrome · Eclampsia
Primary: Duration of Severe-range Hypertension After Delivery — 38.0; 35.3 hours — p=0.3